$30.11
+0.67 (+2.28%)
Open$29.45
Previous Close$29.44
Day High$31.92
Day Low$29.00
52W High$33.53
52W Low$14.72
Volume—
Avg Volume519.1K
Market Cap1.63B
P/E Ratio—
EPS$-1.64
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.62M | 9.1K | 117.17M |
| Net Income | -64,965,645 | -50,362 | -10,038,830 |
| Profit Margin | -980.9% | -582.6% | -8.6% |
| EBITDA | -73,753,019 | -48,936 | -16,056,956 |
| Free Cash Flow | — | — | -11,744,338 |
| Rev Growth | +147.5% | +60.5% | +1.7% |
| Debt/Equity | — | 0.51 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |